Section 152 is the substantive equivalent of 1961 s. 80 RRB -- the patent-royalty deduction for resident-individual patentees on royalty income from patents registered ON OR AFTER 1-APR-2003 under the Patents Act 1970. The post-1-Apr-2003…
152
Section 152 is the substantive equivalent of 1961 s. 80 RRB -- the patent-royalty deduction for resident-individual patentees on royalty income from patents registered ON OR AFTER 1-APR-2003 under the Patents Act 1970. The post-1-Apr-2003…
Section 152 — - DEDUCTION IN RESPECT OF ROYALTY ON PATENTS
Section 152 is the substantive equivalent of 1961 s. 80RRB -- the patent-royalty deduction for resident-individual patentees on royalty income from patents registered ON OR AFTER 1-APR-2003 under the Patents Act 1970. The post-1-Apr-2003 cut-off coincides with the TRIPS-aligned reform of Indian patent regime. The deduction = whole income or INR 3,00,000, whichever is less, with anti-abuse rules for compulsory-licence royalty (capped at Controller-settled rate) and foreign-source FX-remittance condition (6 months). The provision incentivises Indian individual inventors / patentees vs corporate licensees (which use s. 32 / s. 28 PGBP).
STATUTORY ARCHITECTURE
ELIGIBLE ASSESSEE: resident individual who is a PATENTEE (= person whose patent is registered post-1-Apr-2003 under Patents Act 1970, holding the patent rights). 'Patentee' includes original applicant or successor-in-title. INCOME COVERED: royalty (lump-sum or recurring) for use of patent; consideration for grant of licence, etc. QUANTUM: 100% of royalty income capped at INR 3,00,000 annually. COMPULSORY LICENCE GUARDRAIL (sub-s. 3): Where Controller of Patents grants compulsory licence (typical: Bayer-Natco Nexavar 2012-style), royalty for s. 152 deduction cannot exceed Controller-settled rate. Prevents inflated-royalty claims when statutory licensing applies. FOREIGN-SOURCE FX RULE (sub-s. 4): convertible FX remittance to India within 6 months of tax-year-end OR within RBI-approved extension. Mirrors author-royalty s. 151. Practitioner relevance: limited audience -- typical user is academic / individual-inventor licensing patent to corporates. Most patents are owned by employers (employee-inventor's patent assigned via employment contract); employer/corporate cannot use s. 152 (eligibility limited to individuals).
PLANNING NOTES
(i) PATENTEE STATUS -- ensure patent registered in inventor's individual name (not company name); employment-IP-assignment clauses commonly defeat individual claim. (ii) LICENCE NEGOTIATION -- structure as royalty (capped INR 3L deductible) vs lump-sum-assignment (immediate consideration but full taxable). (iii) COMPULSORY LICENCE EXPOSURE -- pharma / agro patents susceptible; check Controller-rate before claiming royalty. (iv) FX-REMITTANCE -- 6-month strict window; Form A2 / FIRC; competent-authority extension rare. (v) NEW-REGIME (s. 202(1)) interaction -- generally NOT available; opt out for s. 152.
CROSS-REFERENCES